UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 10, 2022
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||||||||
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (919 ) 474-6700
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On May 10, 2022
The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.
(d)Exhibits.
The following exhibit relating to Items 2.02 shall be deemed to be furnished, and not filed:
| Exhibit No. | Description | ||||||||||
| 99.1 | |||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||||||||
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIOVENTUS INC. | |||||||||||
| Date: | By: | /s/ Anthony D’Adamio | |||||||||
Anthony D’Adamio Senior Vice President and General Counsel | |||||||||||
Exhibit 99.1
Bioventus Reports First Quarter Results; Reaffirms Full-Year 2022 Financial Guidance
DURHAM, NC – May 10, 2022 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three months ended April 2, 2022.
Q1 Financial Summary & Recent Highlights:
•Net Sales of $117.3 million, up $35.5 million, or 43.4%, year over year as reported and 8.6% organically*
•Net Loss of ($14.8) million, compared to Net Income of $24.5 million in prior-year period
•Adjusted EBITDA* of $7.1 million, compared to $11.1 million in prior-year period
"We are pleased with our strong start to the year as we continue to build our market penetration and drive growth despite a challenging macro environment. Our commercial organization executed well, and we saw progress with our integration plans,” commented Ken Reali, Bioventus’ chief executive officer. “As we celebrate the 10-year anniversary of Bioventus, we are encouraged by the momentum we’re seeing across our key short- and mid-term growth drivers, which position us for sustained double-digit growth and margin expansion."
*See below under “Use of Non-GAAP Financial Measures” for more details.
First Quarter 2022 Financial Results:
The following table represents net sales by geographic region, and by vertical, for the three months ended April 2, 2022 and April 3, 2021, respectively:
| Three Months Ended | Change | ||||||||||||||||||||||
| ($ thousands, except for percentage) | April 2, 2022 | April 3, 2021 | $ | % | |||||||||||||||||||
| By Geographic Region: | |||||||||||||||||||||||
| U.S. | $ | 104,081 | $ | 74,538 | $ | 29,543 | 39.6 | % | |||||||||||||||
| International | 13,209 | 7,240 | 5,969 | 82.4 | % | ||||||||||||||||||
| Net Sales | $ | 117,290 | $ | 81,778 | $ | 35,512 | 43.4 | % | |||||||||||||||
| By Vertical: | |||||||||||||||||||||||
| Pain Treatments | $ | 52,053 | $ | 41,530 | $ | 10,523 | 25.3 | % | |||||||||||||||
| Restorative Therapies | 34,360 | 21,821 | 12,539 | 57.5 | % | ||||||||||||||||||
| Surgical Solutions | 30,877 | 18,427 | 12,450 | 67.6 | % | ||||||||||||||||||
| Net Sales | $ | 117,290 | $ | 81,778 | $ | 35,512 | 43.4 | % | |||||||||||||||
Net sales were $117.3 million compared to $81.8 million for the first quarter of 2021, an increase of $35.5 million, or 43.4%, year-over-year, primarily due to acquisitions. International net sales for the first quarter of 2021 increased 82.4% year over year, or 88.8% on a constant currency* basis.
Gross profit was $75.7 million, or 64.5% of net sales, compared to $59.6 million, or 72.8% of net sales, for the first quarter of 2021, an increase of $16.1 million year-over-year. Non-GAAP gross profit* was $89.1 million, or 76.0% of net sales, compared to $64.8 million, or 79.2% of net sales, for the first quarter of 2021, an increase of $24.3 million year over year.
Operating loss was ($21.5) million, compared to operating income of $22.0 million for the first quarter of 2021, a decrease of ($43.4) million, year-over-year. Operating margin was (18.3%) of net sales, compared to 26.9% of net sales for the first quarter of 2021. Non-GAAP operating income* was $1.9 million, compared to $33.5 million for the first quarter of 2021, a decrease of ($31.6) million year-over-year. Non-GAAP operating margin* was 1.6% of net sales, compared to 40.9% of net sales for the first quarter of 2021.
Net Loss was ($14.8) million compared to net income of $24.5 million for the first quarter of 2021, a decrease of ($39.3) million year-over-year. Non-GAAP net income (loss)* was $2.8 million, compared to $33.4 million, for the first quarter of 2021, a decrease of ($30.6) million, year-over-year.
Adjusted EBITDA* was $7.1 million, compared to $11.1 million for the first quarter of 2021, a decrease of ($4.0) million year-over-year.
Balance Sheet:
As of April 2, 2022, the Company had $27.4 million in cash and cash equivalents and $368.3 million in debt obligations, compared to $43.9 million in cash and cash equivalents and $357.7 million in debt obligations as of December 31, 2021.
Reaffirms Full Year 2022 Financial Guidance:
For the twelve months ending December 31, 2022, the Company expects:
•Net sales of $545 million to $565 million, representing year over year growth of approximately 26% to 31%.
•Adjusted EBITDA* of $94 million to $107 million, compared to $80.8 million for the year ended December 31, 2021.
The Company does not provide U.S. GAAP financial measures, other than net sales, on a forward-looking basis because the Company is unable to predict with reasonable certainty the impact and timing of acquisition related expenses, accounting fair-value adjustments, and other reconciling items without unreasonable efforts. These items are uncertain, depend on various factors, and could be material to the Company’s results computed in accordance with U.S. GAAP.
*See below under “Use of Non-GAAP Financial Measures” for more details.
The Company is not providing guidance for adjusted diluted earnings per share due to the uncertainty of the timing for its potential CartiHeal acquisition, but will provide guidance after completion of any acquisition.
The Company's guidance reflects its current expectations regarding the impact of COVID-19 on its business. The severity and duration of the COVID-19 pandemic are outside of the Company’s control and, given the uncertain nature of the pandemic, could cause the Company’s future operating results to be different from our current expectations, particularly if the impact of the pandemic worsens.
Presentation: This press release presents historical results, for the periods presented, of Bioventus Inc., including Bioventus LLC, the predecessor of Bioventus Inc. for financial reporting purposes.
First Quarter 2022 Earnings Conference Call:
Management will host a conference call to discuss the Company’s financial results and provide a business update, with a question and answer session, at 8:30 a.m. Eastern Time on May 10, 2022. Those who would like to participate may dial 844-945-2085 (442-268-1266 for international callers) and provide access code 1795461.
A live webcast of the call and any accompanying materials will also be provided on the investor relations section of the Company's website at https://ir.bioventus.com/.
The webcast will be archived on the Company’s website at https://ir.bioventus.com/ and available for replay until May 9, 2023.
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatments, restorative therapies and surgical solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
*See below under “Use of Non-GAAP Financial Measures” for more details.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning our business strategy, position and operations; expected sales trends, opportunities and growth; the pending acquisition of CartiHeal; expected completion of integration efforts for Bioness and Misonix; expected impacts of the COVID-19 pandemic; and the Company’s financial guidance and expected financial performance. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release include, but are not limited to, statements about the adverse impacts on our business as a result of the COVID-19 pandemic; our dependence on a limited number of products; our ability to develop, acquire and commercialize new products, line extensions or expanded indications; we may be unable to raise the capital necessary to complete the CartiHeal acquisition and our ability to raise additional funds in the future may be limited; if we are unable to consummate the CartiHeal transaction, we will incur substantial costs and may be subject to forfeiture of the $50.0 million advance paid into escrow or other legal action; the continued and future acceptance of our existing portfolio of products and any new products, line extensions or expanded indications by physicians, patients, third-party payers and others in the medical community; the proposed down-classification of non-invasive bone growth stimulators, including our Exogen system, by the U.S. Food and Drug Administration ("FDA"); our ability to achieve and maintain adequate levels of coverage and/or reimbursement for our products, the procedures using our products, or any future products we may seek to commercialize, including any potential changes by Centers for Medicare and Medicaid Services in the manner in which our HA viscosupplementation products are reimbursed; our ability to complete acquisitions or successfully integrate new businesses, products or technologies in a cost-effective and non-disruptive manner; competition against other companies and consolidation in our industry; the negative impact on our ability to market our HA products due to the reclassification of HA products from medical devices to drugs in the United States by the FDA; our ability to attract, retain and motivate our senior management and qualified personnel; our ability to continue to research, develop and manufacture our products if our facilities are damaged or become inoperable; failure to comply with the extensive government regulations related to our products and operations; enforcement actions if we engage in improper claims submission practices or in improper marketing or promotion of our products; the FDA regulatory process and our ability to obtain and maintain required regulatory clearances and approvals; failure to comply with the government regulations that apply to our human cells, tissues and cellular or tissue-based products; the clinical studies of any of our future products that do not produce results necessary to support regulatory clearance or approval in the United States or elsewhere; and the other risks identified in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission (“SEC”), including Bioventus’ Annual Report on Form 10-K for the year ended December 31, 2021, and as updated by Bioventus' Quarterly Report on Form 10-Q for the quarter ended April 2, 2022 and as may be further updated from time to time in Bioventus’ other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Bioventus’ website at . Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ materially from those set forth in the forward-looking statements.
Consolidated balance sheets
As of April 2, 2022 and December 31, 2021
(Amounts in thousands, except share amounts) (unaudited)
| April 2, 2022 | December 31, 2021 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 27,374 | $ | 43,933 | |||||||
| Restricted cash | 5,280 | 5,280 | |||||||||
| Accounts receivable, net | 119,288 | 124,963 | |||||||||
| Inventory | 64,691 | 61,688 | |||||||||
| Prepaid and other current assets | 28,762 | 27,239 | |||||||||
| Total current assets | 245,395 | 263,103 | |||||||||
| Restricted cash, less current portion | 50,000 | 50,000 | |||||||||
| Property and equipment, net | 24,856 | 22,985 | |||||||||
| Goodwill | 147,968 | 147,623 | |||||||||
| Intangible assets, net | 681,369 | 695,193 | |||||||||
| Operating lease assets | 18,738 | 17,186 | |||||||||
| Deferred tax assets | — | 481 | |||||||||
| Investment and other assets | 28,811 | 29,291 | |||||||||
| Total assets | $ | 1,197,137 | $ | 1,225,862 | |||||||
| Liabilities and Members’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 22,500 | $ | 16,915 | |||||||
| Accrued liabilities | 124,804 | 131,473 | |||||||||
| Accrued equity-based compensation | — | 10,875 | |||||||||
| Current portion of long-term debt | 20,292 | 18,038 | |||||||||
| Other current liabilities | 3,926 | 3,558 | |||||||||
| Total current liabilities | 171,522 | 180,859 | |||||||||
| Long-term debt, less current portion | 348,039 | 339,644 | |||||||||
| Deferred income taxes | 116,020 | 133,518 | |||||||||
| Contingent consideration | 16,598 | 16,329 | |||||||||
| Other long-term liabilities | 23,040 | 21,723 | |||||||||
| Total liabilities | 675,219 | 692,073 | |||||||||
| Stockholders’ Equity: | |||||||||||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued | |||||||||||
Class A common stock, $0.001 par value 250,000,000 shares authorized as of April 2, 2022 and December 31, 2021, 61,357,270 and 59,548,504 shares issued and outstanding as of April 2, 2022 and December 31, 2021, respectively | 62 | 59 | |||||||||
Class B common stock, $0.001 par value, 50,000,000 shares authorized, 15,786,737 shares issued and outstanding as of April 2, 2022 and December 31, 2021 | 16 | 16 | |||||||||
| Additional paid-in capital | 467,940 | 465,272 | |||||||||
| Accumulated deficit | (17,879) | (6,602) | |||||||||
| Accumulated other comprehensive (loss) income | (363) | 179 | |||||||||
| Total stockholders’ equity attributable to Bioventus Inc. | 449,776 | 458,924 | |||||||||
| Noncontrolling interest | 72,142 | 74,865 | |||||||||
| Total stockholders’ equity | 521,918 | 533,789 | |||||||||
| Total liabilities and stockholders’ equity | $ | 1,197,137 | $ | 1,225,862 | |||||||
Consolidated statements of operations and comprehensive (loss) income
(Amounts in thousands, except share and per share data, unaudited)
| Three Months Ended | |||||||||||
| April 2, 2022 | April 3, 2021 | ||||||||||
| Net sales | $ | 117,290 | $ | 81,778 | |||||||
Cost of sales (including depreciation and amortization of $9,218 and $5,236, respectively) | 41,588 | 22,222 | |||||||||
| Gross profit | 75,702 | 59,556 | |||||||||
| Selling, general and administrative expense | 86,124 | 34,686 | |||||||||
| Research and development expense | 6,928 | 947 | |||||||||
| Restructuring costs | 577 | — | |||||||||
| Change in fair value of contingent consideration | 269 | — | |||||||||
| Depreciation and amortization | 3,254 | 1,925 | |||||||||
| Operating (loss) income | (21,450) | 21,998 | |||||||||
| Interest income, net | (1,550) | (2,876) | |||||||||
| Other expense | 38 | 419 | |||||||||
| Other income | (1,512) | (2,457) | |||||||||
| (Loss) income before income taxes | (19,938) | 24,455 | |||||||||
| Income tax benefit | (5,132) | (73) | |||||||||
| Net (loss) income | (14,806) | 24,528 | |||||||||
| Loss attributable to noncontrolling interest | 3,529 | 408 | |||||||||
| Net (loss) income attributable to Bioventus Inc. | $ | (11,277) | $ | 24,936 | |||||||
| Net (loss) income | $ | (14,806) | $ | 24,528 | |||||||
| Other comprehensive (loss) income, net of tax | |||||||||||
| Change in foreign currency translation adjustments | (682) | (1,156) | |||||||||
| Comprehensive (loss) income | (15,488) | 23,372 | |||||||||
| Comprehensive loss attributable to noncontrolling interest | 3,669 | 408 | |||||||||
| Comprehensive (loss) income attributable to Bioventus Inc. | $ | (11,819) | $ | 23,780 | |||||||
Loss per share of Class A common stock(1): | |||||||||||
| Basic and diluted | $ | (0.19) | $ | (0.02) | |||||||
Weighted-average shares of Class A common stock outstanding(1): | |||||||||||
| Basic and diluted | 60,484,969 | 41,797,882 | |||||||||
(1) Per share information for the three months ended April 3, 2021 represents loss per share of Class A common stock and weighted-average shares of Class A common stock outstanding from February 16, 2021 through April 3, 2021, the period following Bioventus Inc.'s initial public offering and related transactions described in Note 1. Organization and Note 8. Earnings per share within the Notes to the Unaudited Condensed Consolidated Financial Statements in the Company's Quarterly Report on Form 10-Q for the quarter ended April 2, 2022. | |||||||||||
Consolidated condensed statements of cash flows
(Amounts in thousands, unaudited)
| Three Months Ended | |||||||||||
| April 2, 2022 | April 3, 2021 | ||||||||||
| Operating activities: | |||||||||||
| Net (loss) income | $ | (14,806) | $ | 24,528 | |||||||
| Adjustments to reconcile net income to net cash from operating activities: | |||||||||||
| Depreciation and amortization | 12,479 | 7,184 | |||||||||
| Equity-based compensation | 4,889 | (22,412) | |||||||||
| Change in fair value of contingent consideration | 269 | — | |||||||||
| Change in fair value of Equity Participation Rights | — | (2,774) | |||||||||
| Change in fair value of interest rate swap | (3,924) | (1,565) | |||||||||
| Impairments related to variable interest entity | — | — | |||||||||
| Deferred income taxes | (17,018) | 83 | |||||||||
| Other, net | 1,399 | 583 | |||||||||
| Changes in working capital | (4,307) | (23,669) | |||||||||
| Net cash from operating activities | (21,019) | (18,042) | |||||||||
| Investing activities: | |||||||||||
| Acquisitions, net of cash acquired | (236) | (45,791) | |||||||||
| Purchase of property and equipment | (2,960) | (1,370) | |||||||||
| Investments and acquisition of distribution rights | (1,478) | 513 | |||||||||
| Net cash from investing activities | (4,674) | (46,648) | |||||||||
| Financing activities: | |||||||||||
| Proceeds from issuance of Class A common stock sold in initial public offering, net of underwriting discounts and offering costs | — | 110,410 | |||||||||
| Proceeds from issuance of Class A and B common stock | 2,080 | 16 | |||||||||
| Tax withholdings on equity-based compensation | (3,352) | — | |||||||||
| Borrowing on revolver | 15,000 | — | |||||||||
| Payments on long-term debt | (4,509) | (3,750) | |||||||||
| Refunds from members | — | 854 | |||||||||
| Other, net | (14) | (4) | |||||||||
| Net cash from financing activities | 9,205 | 107,526 | |||||||||
| Effect of exchange rate changes on cash | (71) | (221) | |||||||||
| Net change in cash, cash equivalents and restricted cash | (16,559) | 42,615 | |||||||||
| Cash, cash equivalents and restricted cash at the beginning of the period | 99,213 | 86,839 | |||||||||
| Cash, cash equivalents and restricted cash at the end of the period | $ | 82,654 | $ | 129,454 | |||||||
Use of Non-GAAP Financial Measures
Net Sales and International Net Sales Growth on a Constant Currency Basis
Net Sales and International Net Sales Growth on a Constant Currency Basis are non-GAAP measures, which are calculated by translating current and prior year results at the same foreign currency exchange rate. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to facilitate the comparison sales in foreign currencies to prior periods and analyze net sales performance without the impact of changes in foreign currency exchange rates.
Organic Revenue Growth
The Company defines the term “organic revenue” as revenue in the stated period excluding the impact from business acquisitions and divestitures. The Company uses the related term “organic revenue growth” to refer to the financial performance metric of comparing the stated period organic revenue with the reported revenue of the corresponding period in the prior year. The Company believes that these non-GAAP financial measures, when taken together with our GAAP financial measures, allows the Company and its investors to better measure the Company’s performance and evaluate long-term performance trends. Organic revenue growth also facilitates easier comparisons of the Company’s performance with prior and future periods and relative comparisons to its peers. The Company excludes the effect of acquisitions and divestitures because these activities can have a significant impact on the Company's reported results, which the Company believes makes comparisons of long-term performance trends difficult for management and investors.
Adjusted EBITDA, Non-GAAP Gross Profit, Non-GAAP Gross Margin, Non-GAAP Operating Income, Non-GAAP Operating Expense, Non-GAAP Operating Margin, Non-GAAP Net Income, and Non-GAAP Earnings per share of Class A Common Stock.
We present Adjusted EBITDA, Non-GAAP Gross Profit, Non-GAAP Gross Margin, Non-GAAP Operating Income, Non-GAAP Operating Expense, Non-GAAP Operating Margin, Non-GAAP Net Income, and Non-GAAP Earnings per share of Class A Common Stock, all non-GAAP financial measures, to supplement our financial reporting, because we believe these measures are useful indicators of our operating performance. We revised our prior year presentation of our Non-GAAP measures to condense the adjustments in order to simplify the presentation. Prior periods have been recast to conform to the current period.
We define Adjusted EBITDA as net income (loss) from continuing operations before depreciation and amortization, provision of income taxes and interest expense (income), adjusted for the impact of certain cash, non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include acquisition and related costs, restructuring and succession charges, equity compensation, equity loss in unconsolidated investments, foreign currency impact, and other items. See the table below for a reconciliation of net income to Adjusted EBITDA. Our management uses Adjusted EBITDA principally as a measure of our operating performance and believes that Adjusted EBITDA is useful to our investors because it is frequently used by securities analysts, investors and other interested parties often use it in their evaluation of the operating performance of companies in industries similar to ours. Our management also uses Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections.
Our management uses Non-GAAP Gross Profit, Non-GAAP Gross Margin, Non-GAAP Operating Income, Non-GAAP Operating Expense, Non-GAAP Operating Margin and Non-GAAP Net Income principally as measures of our operating performance and believe that these non-GAAP financial measures are useful to better understand the long term performance of our core business and to facilitate comparison of our results to those of peer companies. Our management also uses these non-GAAP financial measures for planning purposes, including the preparation of our annual operating budget and financial projections.
We define Non-GAAP Gross Profit as gross profit, adjusted for the impact of certain cash, non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include depreciation and amortization included in the cost of goods sold and acquisition and related costs in the cost of goods sold. We define Non-GAAP Gross Margin as Non-GAAP Gross Profit divided by net sales. See the table below for a reconciliation of gross profit and gross margin to Non-GAAP Gross Profit and Non-GAAP Gross Margin.
We define Non-GAAP Operating Income as operating income, adjusted for the impact of certain cash, non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include depreciation and amortization, acquisition and related costs, restructuring and succession charges, and other items. Non-GAAP Operating Margin is defined as Non-GAAP Operating Income divided by net sales. See the table below for a reconciliation of Operating Income and operating margin to Non-GAAP Operating Income and Non-GAAP Operating Margin.
We define Non-GAAP Operating Expense as operating expenses, adjusted to exclude certain cash, non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include depreciation and amortization, acquisition and related costs, restructuring and succession charges, and other items. See the table below for a reconciliation of Operating Expenses to Non-GAAP Operating Expenses.
We define Non-GAAP Net Income as Net Income, adjusted for the impact of certain cash, non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include depreciation and amortization, acquisition and related costs, restructuring and succession charges, other items, and the tax effect of adjusting items. Starting in the fourth quarter of 2021, we revised our presentation of Non-GAAP Net Income to include the income tax effect of adjusting items. The income tax effect was calculated by applying management's expectation of a long-term normalized effective tax rate to the adjusting items. Prior period presentation has been recast to conform to current period presentation. See the table below for a reconciliation of Net Income to Non-GAAP Net Income.
We define Non-GAAP Earnings per Class A share as Earnings per Class A share, adjusted for the impact of certain cash, non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include depreciation and amortization, acquisition and related costs, restructuring and succession charges, other items, and the tax effect of adjusting items divided by weighted average number of shares of Class A common stock outstanding during the period. Starting in the fourth quarter of 2021, we revised our presentation of Non-GAAP Earnings per Class A share to include the income tax effect of adjusting items. The income tax effect was calculated by applying management's expectation of a long-term normalized effective tax rate to the adjusting items. Prior period presentation has been recast to conform to current period presentation. See the table below for a reconciliation of loss per Class A share to Non-GAAP Earnings per Class A share.
Reconciliation of Net (Loss) Income to Adjusted EBITDA (unaudited)
| Three Months Ended | |||||||||||
| ($, thousands) | April 2, 2022 | April 3, 2021 | |||||||||
| Net (loss) income | $ | (14,806) | $ | 24,528 | |||||||
| Interest income, net | (1,550) | (2,876) | |||||||||
| Income tax benefit | (5,132) | (73) | |||||||||
Depreciation and amortization(a) | 12,479 | 7,184 | |||||||||
Acquisition and related costs(b) | 7,403 | 3,196 | |||||||||
Restructuring and succession charges(c) | 577 | 157 | |||||||||
Equity compensation(d) | 4,889 | (22,412) | |||||||||
Equity loss in unconsolidated investments(e) | 401 | 469 | |||||||||
Foreign currency impact(f) | (61) | (52) | |||||||||
Other items(g) | 2,911 | 949 | |||||||||
| Adjusted EBITDA | $ | 7,111 | $ | 11,070 | |||||||
(a)Includes for the three months ended April 2, 2022 and April 3, 2021, respectively, depreciation and amortization of $9,218 and $5,236 in cost of sales and $3,261 and $1,948 in operating expenses presented in the consolidated statements of operations and comprehensive (loss) income.
(b)Includes acquisition and integration costs related to completed acquisitions, amortization of inventory step-up associated with acquired entities, and changes in fair value of contingent consideration.
(c)Costs incurred during 2022 were the result of adopting acquisition related restructuring plans to reduce headcount, reorganize management structure and to consolidate certain facilities. Costs in 2021 primarily related to executive transitions.
(d)The three months ended April 2, 2022 includes compensation expense resulting from awards granted under the Company’s equity based compensation plans. The three months ended April 3, 2021 primarily includes the change in fair value of the liability-classified awards granted under the Management incentive plan (MIP) prior to the IPO, partially offset by compensation expense resulting from awards granted under the Company's equity based compensation plans in effect after its IPO.
(e)Includes CartiHeal equity investment losses.
(f)Includes realized and unrealized gains and losses from fluctuations in foreign currency.
(g)Other items primarily includes charges associated with strategic transactions, such as potential acquisitions, and public company preparation costs, which primarily includes accounting and legal fees.
Reconciliation of Other Reported GAAP Measures to Non-GAAP Measures
| Three Months Ended April 2, 2022 | Gross Profit | Operating Expenses | Operating Income | Net Income/Loss | EPS(f) | ||||||||||||||||||||||||
| Reported GAAP measure | $ | 75,702 | $ | 97,152 | $ | (21,450) | $ | (14,806) | $ | (0.19) | |||||||||||||||||||
| Reported GAAP margin | 64.5 | % | (18.3) | % | |||||||||||||||||||||||||
Depreciation and amortization(a) | 9,218 | 3,261 | 12,479 | 12,479 | 0.16 | ||||||||||||||||||||||||
Acquisition and related costs(b) | 4,205 | 3,198 | 7,403 | 7,403 | 0.10 | ||||||||||||||||||||||||
Restructuring and succession charges(c) | — | 577 | 577 | 577 | 0.01 | ||||||||||||||||||||||||
Other items(d) | — | 2,911 | 2,911 | 2,911 | 0.04 | ||||||||||||||||||||||||
Tax effect of adjusting items(e) | — | — | — | (5,803) | (0.08) | ||||||||||||||||||||||||
| Non-GAAP measure | $ | 89,125 | $ | 87,205 | $ | 1,920 | $ | 2,761 | $ | 0.04 | |||||||||||||||||||
| Non-GAAP margin | 76.0 | % | 1.6 | % | |||||||||||||||||||||||||
| Non-GAAP Gross Margin | Non-GAAP Operating Expenses | Non-GAAP Operating Income | Non-GAAP Net Income | Adjusted EPS | |||||||||||||||||||||||||
| Three Months Ended April 3, 2021 | Gross Profit | Operating Expenses | Operating Income | Net Income | EPS(f) | ||||||||||||||||||||||||
| Reported GAAP measure | $ | 59,556 | $ | 37,558 | $ | 21,998 | $ | 24,528 | $ | (0.02) | |||||||||||||||||||
| Reported GAAP margin | 72.8 | % | 26.9 | % | |||||||||||||||||||||||||
Depreciation and amortization(a) | 5,236 | 1,948 | 7,184 | 7,184 | 0.12 | ||||||||||||||||||||||||
Acquisition and related costs(b) | — | 3,196 | 3,196 | 3,196 | 0.06 | ||||||||||||||||||||||||
Restructuring and succession charges(c) | — | 157 | 157 | 157 | — | ||||||||||||||||||||||||
Other items(d) | — | 949 | 949 | 949 | 0.02 | ||||||||||||||||||||||||
Tax effect of adjusting items(e) | — | — | — | (2,622) | (0.05) | ||||||||||||||||||||||||
| Non-GAAP measure | $ | 64,792 | $ | 31,308 | $ | 33,484 | $ | 33,392 | $ | 0.13 | |||||||||||||||||||
| Non-GAAP margin | 79.2 | % | 40.9 | % | |||||||||||||||||||||||||
| Non-GAAP Gross Margin | Non-GAAP Operating Expenses | Non-GAAP Operating Income | Non-GAAP Net Income | Adjusted EPS | |||||||||||||||||||||||||
(a)Includes for the three months ended April 2, 2022 and April 3, 2021 respectively, depreciation and amortization of $9,218 and $5,236 in cost of sales and $3,261 and $1,948 in operating expenses presented in the consolidated statements of operations and comprehensive income
(b)Consists of acquisition related items such as integration costs, amortization of inventory step-up, and changes in fair value of contingent consideration.
(c)Consists of restructuring plans to reduce headcount, reorganize management structure and consolidate certain facilities, as well as executive leadership transition costs.
(d)Other items primarily consists of charges associated with strategic transactions, such as potential acquisitions, and debt retirement and modification costs.
(e)Calculated by applying a normalized statutory rate of 24.8% and 22.8%, respectively, to the adjustments to Non-GAAP Net Income for the three months ended April 2, 2022 and April 3, 2021. The tax effect on adjustments to EPS is normalized to exclude the effect of the non-controlling ownership interest.
(f)Adjustments are pro-rated to exclude the weighted average non-controlling interest ownership of 20.5% and 27.80%, respectively, for the three months ended April 2, 2022 and April 3, 2021.
Investor Inquiries:
Dave Crawford
Bioventus
investor.relations@bioventus.com
Press and Media Inquiries:
Jamica Whitaker
Bioventus
jamica.whitaker@bioventus.com